Startups
Swiss startup Atlas Bio secures $12.5M to tackle drug development’s 70% failure rate and move beyond animal testing
Atlas Bio, a Swiss biotech startup, raised $12.5 million to develop an AI foundation model that simulates clinical trials and aims to replace Phase II drug trials and animal testing.